Table of Contents Author Guidelines Submit a Manuscript
Contrast Media & Molecular Imaging
Volume 2017 (2017), Article ID 7498538, 8 pages
https://doi.org/10.1155/2017/7498538
Research Article

Molecular Imaging to Predict Response to Targeted Therapies in Renal Cell Carcinoma

1IR4M, UMR 8081, Paris-Sud University, CNRS, Bâtiment 220, rue Ampère, 91405 Orsay Cedex, France
2Gustave Roussy, 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France
3Service Urologie, Hôpital Bicêtre, 78 rue du Général Leclerc, 94270 Le Kremlin-Bicêtre, France
4Experimental Imaging, MRI Unit, Research Division, Guerbet, 93600 Aulnay-sous-Bois, France

Correspondence should be addressed to Ingrid Leguerney; rf.yssuorevatsug@yenreugel.dirgni

Received 9 September 2016; Revised 26 January 2017; Accepted 9 March 2017; Published 9 April 2017

Academic Editor: Anne Roivainen

Copyright © 2017 Ingrid Leguerney et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. J. Motzer, T. E. Hutson, P. Tomczak et al., “Sunitinib versus interferon alfa in metastatic renal-cell carcinoma,” New England Journal of Medicine, vol. 356, no. 2, pp. 115–124, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. M. Claudon, C. F. Dietrich, B. I. Choi et al., “Guidelines and Good Clinical Practice Recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver—update 2012. A WFUMB-EFSUMB Initiative in Cooperation with Representatives of AFSUMB, AIUM, ASUM, FLAUS and ICUS,” Ultrasound in Medicine and Biology, vol. 39, no. 2, pp. 187–210, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. C. F. Dietrich, M. A. Averkiou, J.-M. Correas, N. Lassau, E. Leen, and F. Piscaglia, “An EFSUMB introduction into dynamic contrast-enhanced ultrasound (DCE-US) for quantification of tumour perfusion,” Ultraschall in der Medizin, vol. 33, no. 4, pp. 344–351, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. N. Lassau, S. Koscielny, L. Albiges et al., “Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography,” Clinical Cancer Research, vol. 16, no. 4, pp. 1216–1225, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. J. P. O'Connor, E. O. Aboagye, J. E. Adams et al., “Imaging biomarker roadmap for cancer studies,” Nature Reviews Clinical Oncology, vol. 14, no. 3, pp. 169–186, 2017. View at Google Scholar
  6. N. Deshpande, M. A. Pysz, and J. K. Willmann, “Molecular ultrasound assessment of tumor angiogenesis,” Angiogenesis, vol. 13, no. 2, pp. 175–188, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Kiessling, S. Fokong, P. Koczera, W. Lederle, and T. Lammers, “Ultrasound microbubbles for molecular diagnosis, therapy, and theranostics,” Journal of Nuclear Medicine, vol. 53, no. 3, pp. 345–348, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. M. A. McAteer and R. P. Choudhury, “Targeted molecular imaging of vascular inflammation in cardiovascular disease using nano- and micro-sized agents,” Vascular Pharmacology, vol. 58, no. 1-2, pp. 31–38, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. A. H. Smith, H. Fujii, M. A. Kuliszewski, and H. Leong-Poi, “Contrast ultrasound and targeted microbubbles: diagnostic and therapeutic applications for angiogenesis,” Journal of Cardiovascular Translational Research, vol. 4, no. 4, pp. 404–415, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. D. B. Ellegala, H. Leong-Poi, J. E. Carpenter et al., “Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to αvβ3,” Circulation, vol. 108, no. 3, pp. 336–341, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. T. Huo, X. Du, S. Zhang, X. Liu, and X. Li, “Gd-EDDA/HYNIC-RGD as an MR molecular probe imaging integrin ανβ3 receptor-expressed tumor—MR molecular imaging of angiogenesis,” European Journal of Radiology, vol. 73, no. 2, pp. 420–427, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. A. H. Schmieder, P. M. Winter, S. D. Caruthers et al., “Molecular MR imaging of melanoma angiogenesis with ανβ3-targeted paramagnetic nanoparticles,” Magnetic Resonance in Medicine, vol. 53, no. 3, pp. 621–627, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. P. M. Winter, S. D. Caruthers, J. S. Allen et al., “Molecular imaging of angiogenic therapy in peripheral vascular disease with ανβ3-integrin-targeted nanoparticles,” Magnetic Resonance in Medicine, vol. 64, no. 2, pp. 369–376, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. I. Leguerney, N. Lassau, S. Koscielny et al., “Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments,” Investigational New Drugs, vol. 30, no. 1, pp. 144–156, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Lavisse, P. Lejeune, V. Rouffiac et al., “Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrast-enhanced ultrasonography,” Investigative Radiology, vol. 43, no. 2, pp. 100–111, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. N. Lassau, J. Bonastre, M. Kind et al., “Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study,” Investigative Radiology, vol. 49, no. 12, pp. 794–800, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. N. Lassau, S. Koscielny, L. Chami et al., “Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced us with quantification—preliminary results,” Radiology, vol. 258, no. 1, pp. 291–300, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Lassau, D. Cosgrove, and J.-P. Armand, “Early evaluation of targeted drugs using dynamic contrast-enhanced ultrasonography for personalized medicine,” Future Oncology, vol. 8, no. 10, pp. 1215–1218, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. O. M. Hahn, C. Yang, M. Medved et al., “Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma,” Journal of Clinical Oncology, vol. 26, no. 28, pp. 4572–4578, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. F. A. Howe, S. P. Robinson, D. J. O. McIntyre, M. Stubbs, and J. R. Griffiths, “Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours,” NMR in Biomedicine, vol. 14, no. 7-8, pp. 497–506, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. A. R. Padhani and M. O. Leach, “Antivascular cancer treatments: functional assessments by dynamic contrast-enhanced magnetic resonance imaging,” Abdominal Imaging, vol. 30, no. 3, pp. 324–341, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Toschi, E. Lee, N. Gadir, M. Ohh, and D. A. Foster, “Differential dependence of hypoxia-inducible factors 1α and 2α on mTORC1 and mTORC2,” The Journal of Biological Chemistry, vol. 283, no. 50, pp. 34495–34499, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Ljungberg, N. C. Cowan, D. C. Hanbury et al., “EAU guidelines on renal cell carcinoma: the 2010 update,” European Urology, vol. 58, no. 3, pp. 398–406, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. C. Ravelli, S. Mitola, M. Corsini, and M. Presta, “Involvement of αvβ3 integrin in gremlin-induced angiogenesis,” Angiogenesis, vol. 16, no. 1, pp. 235–243, 2013. View at Publisher · View at Google Scholar · View at Scopus
  25. J. S. Desgrosellier, L. A. Barnes, D. J. Shields et al., “An integrin α v Β 3-c-Src oncogenic unit promotes anchorage-independence and tumor progression,” Nature Medicine, vol. 15, no. 10, pp. 1163–1169, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. D. A. Sipkins, D. A. Cheresh, M. R. Kazemi, L. M. Nevin, M. D. Bednarski, and K. C. P. Li, “Detection of tumor angiogenesis in vivo by α(v)β3-targeted magnetic resonance imaging,” Nature Medicine, vol. 4, no. 5, pp. 623–626, 1998. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Bex, L. Fournier, N. Lassau et al., “Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations,” European Urology, vol. 65, no. 4, pp. 766–777, 2014. View at Publisher · View at Google Scholar · View at Scopus
  28. H. C. Kang, K.-S. Tan, S. M. Keefe et al., “MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib,” American Journal of Roentgenology, vol. 200, no. 1, pp. 120–126, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. P. Therasse, S. G. Arbuck, E. A. Eisenhauer et al., “New guidelines to evaluate the response to treatment in solid tumors,” Journal of the National Cancer Institute, vol. 92, no. 3, pp. 205–216, 2000. View at Publisher · View at Google Scholar · View at Scopus